Active Filter(s):
Details:
Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Idelalisib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CAL101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $81.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 22, 2024